Brooks Laboratories Q4 FY26 Preview: Revenue Growth Expectations and Earnings Outlook

Mon Mar 16 2026

Brooks Laboratories Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Brooks Laboratories was listed on the National Stock Exchange (NSE) on 05-Sep-2011. Brooks Laboratories share has its face value of 10 per share, and its NSE symbol is BROOKS. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

Brooks Laboratories Q4 Results 2026 Preview

Brooks Laboratories Q4 FY26 revenue is expected to be around Stable Performance, representing a 12% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 13% YoY.
EBITDA to rise 11%.
Brooks Laboratories is expected to show Stable Performance in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Brooks Laboratories Share Performance

Over the past six months, Brooks Laboratories share price has positive by 4% to 57.61.
Moreover, over the past year, the stock has positive by 14%
Despite this weak short-term performance, Brooks Laboratories stock has delivered a financially sound 96% return over the past 5 years.
As of today, 13-03-2026, the Brooks Laboratories share price is trading at 57.61 per share.

Key Factors to Watch for Brooks Laboratories Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Brooks Laboratories

Brooks Laboratories operates in the pharmaceutical manufacturing sector focusing on injectable formulations and contract manufacturing services. The company continues expanding export markets and improving production efficiency.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Brooks Laboratories is gear up to announce its Q4 FY26 results. Analysts expect 12% revenue growth, a 13% rise in PAT, and a 11% rise in EBITDA. Brooks Laboratories focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Brooks Laboratories Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.